Current Gold Standards for MSI Testing and the Clinical Relevance of the MSI-H Biomarker
In this webinar, you will be able to:
- Describe the different techniques to measure MSI and compare to current gold-standard methods
- Explain the clinical utility of the MSI biomarker for Lynch syndrome screening and immunotherapy treatment
- Discuss current clinical practice guidelines for MSI testing
C.E. Credits: P.A.C.E. CE | Florida CE | CPD
Summary
Promega is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
Promega is also a premier partner of CE Broker, the official tracking system of the Florida Board of Clinical Laboratory Personnel.
Level of Instruction: Intermediate
Number of Contact Hours: 1
(For P.A.C.E. credit, criteria must be completed within 6 months of registration.)
This activity is accredited by the CPD Standards Office which equates to 1 CPD hour.
*It is the registrant's responsibility to verify the applicability of the offered credits to meet individual continuing education requirements.
Historically MSI has been used to screen for Lynch syndrome, a dominant hereditary cancer propensity. Since 2015, MSI status has been rediscovered as a biomarker for immunotherapeutic response, making MSI status an increasingly relevant tool for genetics and immuno-oncology applications. In this webinar, we will discuss MSI testing gold standards and compare the different methods that are currently being used for MSI testing for mismatch repair deficient (dMMR) tumors. We will also discuss the clinical relevance of the MSI-H biomarker focusing on the pathological and epidemiological characteristics of MSI-H/dMMR tumors, and the role of MSI testing in Lynch syndrome screening, colorectal cancer patient prognosis, and immunotherapy treatment.
Speaker
Annette Burkhouse, PhD
Senior Medical Science Liaison
Promega Corporation